glp-1 and alcohol use disorder receptor agonists show promise in treating substance disorders IUPHAR review – Glucagon-like peptide-1
Description
around 10% are affected by the most severe
Strategies to facilitate medication adherence, persistence and treatment intensification in people with T2D should be made a priority in order to achieve and maintain glycaemic targets and improve outcomes in this population
Alcohol worsens GI, non-diabetics identical, urinary/eye/mental effects covered.
Order today.
As of January 2021, only 14.2% of plans covered GLP-1s for obesity
